SCHEMBL7764376

SCHEMBL7764376

CCOC(=O)C(CC(=O)O)(C(=O)O)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.39
CYP2D6 P10635 2/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
HIF1A Q16665 1/20 0.39
ALDH1A1 P00352 4/20 0.39
PIN1 Q13526 1/20 0.38
PKM P14618 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
THRB P10828 1/20 0.36
ALOX15 P16050 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097767 0.91 EGLN1 (0.42) EGLN1CYP2D6TSHRCYP2C19HIF1A
SCHEMBL9794650 0.85 GAA (0.44) ALDH1A1PIN1PKMKDM4EMEN1
SCHEMBL2098303 0.82 CYP4F2 (0.42) EGLN1ALDH1A1PIN1PKMKDM4E
SCHEMBL27918078 0.77 MEN1 (0.48) EGLN1CYP2D6TSHRCYP2C19HIF1A
SCHEMBL28890751 0.77 ALDH1A1 (0.42) CYP2D6TSHRCYP2C19HIF1AALDH1A1
SCHEMBL27567116 0.76 EGLN1 (0.41) EGLN1CYP2D6TSHRCYP2C19HIF1A
SCHEMBL1829725 0.76 CYP4F2 (0.50) EGLN1CYP2D6TSHRCYP2C19HIF1A
SCHEMBL2557186 0.76 ALDH1A1 (0.48) EGLN1ALDH1A1PIN1PKMKDM4E
SCHEMBL11432705 0.74 MEN1 (0.46) EGLN1TSHRCYP2C19ALDH1A1PIN1
SCHEMBL10891188 0.74 POLB (0.42) EGLN1CYP2D6ALDH1A1PIN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9683123-B2 Silver ink PESOLVE CO., LTD. (KR) 2017-06-20 US disclosed
US-20160168408-A1 SILVER INK PESOLVE CO., LTD. (KR) 2016-06-16 US disclosed
EP-0732126-B1 Treatment of organic compounds to reduce chlorine level LUBRIZOL CORP (US) 2001-06-20 EP disclosed
US-5672266-A MIXING ORGANOCHLORINE COMPOUND WITH LEWIS ACID FOR PARTIAL DECHLORINATION IN ABSENCE OF ELEMENTAL CARBON THE LUBRIZOL CORPORATION (US) 1997-09-30 US disclosed
EP-0732126-A1 Treatment of organic compounds to reduce chlorine level The Lubrizol Corporation (US) 1996-09-18 EP disclosed
US-5489390-A TREATING WITH MINERAL OR ORGANIC ACID THE LUBRIZOL CORPORATION (US) 1996-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168408-A1 SILVER INK TP53, MKI67, NRAS EGLN1 2138/4885CYP2D6 1074/4885TSHR 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.